Journal
ANTIVIRAL RESEARCH
Volume 172, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2019.104615
Keywords
Epstein-barr virus; Dipyridamole; Drug repurposing; EBV reactivation
Categories
Funding
- CAPES/COFECUB [Me917/18]
- ICGEB/CNPq [405231/2015-6]
- ANRS
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil
- Sorbonne Universite
Ask authors/readers for more resources
Epstein-Barr virus (EBV) is a widely distributed gamma-herpesvirus that has been associated with various cancers mainly from lymphocytic and epithelial origin. Although EBV-mediated oncogenesis has been associated with viral oncogenes expressed during latency, a growing set of evidence suggested that antiviral treatments directed against EBV lytic phase may contribute to prevent some forms of cancers, including EBV-positive Post-Transplant Lymphoproliferative Diseases. It is shown here that dipyridamole (DIP), a safe drug with favorable and broad pharmacological properties, inhibits EBV reactivation from B-cell lines. DIP repressed immediate early and early genes expression mostly through its ability to inhibit nucleoside uptake. Considering its wide clinical use, DIP repurposing could shortly be evaluated, alone or in combination with other antivirals, to treat EBV-related diseases where lytic replication plays a deleterious role.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available